drugset / Trial / NCT00002687

Interleukin-2 in Treating Patients With Mycosis Fungoides

NCT00002687

Phase 1 Completed 30 enrolled University of Washington
Treatment

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides.

Timeline

Start
1995-02
Primary completion
2003-07
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Subcutaneous

Indications